HOME >> BIOLOGY >> NEWS
Hopkins researchers develop method to predict response to chemotherapy

Researchers at the Johns Hopkins Oncology Center uncovered a genetic alteration that appears to predict how individuals with an aggressive type of brain cancer will respond to chemotherapy.

The discovery, published in the November 9, 2000, issue of the New England Journal of Medicine, emerged from analysis of tumor samples from 47 patients with glioma, all of whom received standard treatment with the drug, carmustine. In 19 of the patients, the methyl-guanine-DNA methyltransferase (MGMT) gene appeared in a chemically altered form and 12 of these 19 had significantly better responses to chemotherapy, including regression of the tumor and increased long-term survival. This is compared with one patient of 28 with unaltered MGMT genes who responded to the chemotherapy. Patients with altered MGMT genes lived an average of 13 months longer than the other patients.

The MGMT gene is altered through a biochemical process known as methylation. The Hopkins scientists speculate that the normal, so-called unmethylated MGMT genes support repair of DNA damage, including damage caused by chemotherapy drugs, and therefore inhibits effectiveness of the drug. When the gene is altered or methylated, however, repair activity is blocked, allowing the anticancer drugs to attack the cancer cells unchecked.

The researchers currently are investigating agents that will block the MGMT gene and increase tumor sensitivity to carmustine. "The ability to detect the methylated form of the MGMT gene may provide a new way of pre-selecting some cancer therapy based on a tumor's chemical profile," says James G. Herman, M.D., assistant professor of oncology at Johns Hopkins and principal investigator of the study.

"The most exciting aspect of this research is that we can begin applying it to therapy right away," says Manel Esteller, M.D., Ph.D., research fellow at the Oncology Center and first author of the paper. "We don't have to wait for new drugs to be develo
'"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
8-Nov-2000


Page: 1 2

Related biology news :

1. Hopkins scientists use blood proteins to detect ovarian cancer
2. Hopkins to found first center for comprehensive study of epigenetics
3. Hopkins scientists overcome main obstacle to making tons of short, drug-like proteins
4. Hopkins Marine Station honored by the American Society for Microbiology
5. Johns Hopkins gene hunters pinpoint new cancer gene target
6. Hopkins researchers identify transplantation antigens among Sioux Indians
7. Hopkins researchers discover how nitric oxide prevents blood vessel inflammation
8. Hopkins is first US institution to obtain powerful genotyping system
9. Dr. Robot tested at Hopkins
10. From Hopkins: Children may outgrow peanut allergies
11. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine

Post Your Comments:
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... non-traditional biophysics textbook and it describes how life functions ... discovery into biological systems and provides an understanding of ... about how our genes make proteins that control the ... in an organism. It quantifies the principles of life ... found on both large and small scales. The book ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: